CBLL - CeriBell EEG Forward Price-to-Revenue Multiple
CeriBell, Inc. (CBLL) management is effectively scaling its fleet of AI systems across US hospitals. The forward price-to-sales valuation trend on the precise GURU.Markets chart shows that the current parameter is 9.40. Growth is driven by the implementation of EEG monitoring in intensive care units and the expansion of insurance coverage, while valuation potential is supported by the intensive development of breakthrough rapid seizure diagnostic algorithms.
Summary analytical data breakdowns for CeriBell EEG (CBLL)
- market price and analyst price targets:
- market capitalization statistics:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital CeriBell, Inc.|CBLL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio CeriBell, Inc.|CBLL - Company Total Debt Obligations|Debts to Book Capitalization CeriBell EEG|CBLL - Company Long-Term Liabilities|Company Short-Term Debts CeriBell|Quick Liquidity ceribell.com
- financial results and valuation multiples details:
CBLL - Company Net Income|Expected Profit CeriBell, Inc.|CBLL - Price to Earnings Ratio|Future Price to Earnings CeriBell Corp|CBLL - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple CeriBell EEG|CBLL - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months CeriBell|CBLL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ceribell.com|CBLL - Earnings per share increase in current year|Net earnings per share growth forecast for next year CeriBell, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:CeriBell CBLL
Rising sales of CeriBell, Inc. (CBLL) disposable sensors across hospital networks are creating a steady cash flow that directly impacts the business's market value. The ratio of current capitalization to projected revenue, illustrated via the forward P/S chart, allows for the valuation of future earnings without the delays of quarterly reporting. This metric's price action helps investors balance potential returns against the risks of asset overvaluation.
Competitors of CeriBell, Inc. (CBLL)
Price-to-Projected Revenue Ratio Biogen BIIB|Neurocrine - Price-to-Projected Revenue Ratio|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACAD: Forward P/S Multiple|XENE - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Market Cap to Projected Revenue SUPN (Supernus Pharmaceuticals, Inc.)|Forward P/S Multiple CPRX|Forward Price-to-Revenue Multiple Denali Corp DNLI|Harmony Biosciences - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio biohavenpharma.com (BHVN)|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Trevi Therapeutics Inc (TRVI) - Forward Price-to-Revenue Multiple|PRAX: Forward P/S Multiple|AVXL (Anavex Life Sciences Corp) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Prothena Biosciences|Price-to-Projected Revenue Ratio ALEC|Price-to-Projected Revenue Ratio Annexon (ANNX)|Price-to-Projected Revenue Ratio OMER (omeros.com)|Price-to-Projected Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Projected Revenue|Voyager Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio neumoratx.com|SCLX (Scilex) - Forward Price-to-Revenue Multiple|Tevogen Bio Holdings Inc. (TVGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alpha Cognition Inc|CGTX: Forward Price to Sales|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA - Market Cap to Future Revenue Ratio|Forward P/S Multiple ASRT (Assertio)|COYA - Forward Price-to-Revenue Multiple|VistaGen Therapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ovid Therapeutics Inc.|Acumen Pharmaceuticals (ABOS) - Price-to-Projected Revenue Ratio|cervomed.com - Forward Price to Sales|ATHE (Alterity Therapeutics Ltd.) - Forward P/S Multiple|Clene Nanomedicine (CLNN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PEPG|Price-to-Projected Revenue Ratio JUNS (Jupiter Neurosciences, Inc.)|Forward P/S Multiple RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|GRCE - Price-to-Projected Revenue Ratio|AIFF: Price-to-Projected Revenue Ratio|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple RVPH|MTVA: Forward Price to Sales|Forward P/S Multiple NRXS|Market Cap to Expected Sales Ratio heliusmedical.com|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP: Market Cap to Projected Revenue|Minerva Neurosciences - Forward P/S Multiple|athira.com (ATHA) - Forward Price-to-Revenue Multiple|ADXN (Addex Therapeutics Ltd) - Forward Price-to-Revenue Multiple|ALZN - Market Cap to Expected Sales Ratio|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Protagenic (PTIX)|Forward P/S Multiple KTTA|Price-to-Projected Revenue Ratio CRGT (cortigent.com)|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|CARA - Price-to-Projected Revenue Ratio|CHRO: Price-to-Projected Revenue Ratio|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Forward Price-to-Revenue Multiple NKGN (NKGen)|Forward P/S Multiple NeuroBo Pharma (NRBO)|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|Forward Price to Sales SNPX|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vigil Neuroscience|WENA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cerevel Corp
